Morgan Lewis partners Christopher Betti and Kathleen Sanzo and associates Richard Martin and Maria Doukas authored an article for Law360 regarding draft guidance issued by the US Food and Drug Administration (FDA) in April 2019 on bispecific antibody development programs. In the article, they discuss key issues identified by the FDA that companies should consider when structuring their patent strategy.